Work is underway on the first pre-clinical panel in PB001. The research is carried out by Timeline Bioresearch, experienced in immuno-oncology and intestinal cancer models.
As forecasted by the Management Board, in late December 2020, a bispecific antibody was administered to the first cohort of mice in a maximum tolerated dose study in an ascending dose schedule. The established maximum tolerated dose will be used in the next stage of the experiment to test the effectiveness of this antibody.
By using models, the company plans to test the research hypothesis of the mechanism of action of the future PB001 molecule.